Common Questions About Participating in Alzheimer’s and Related Dementias Research


How Can I Find Out About Alzheimer’s Trials and Studies?

Check the resources below:

  • Ask your doctor, who may know about local research studies that may be right for you.
  • Sign up for a registry or a matching service to be invited to participate in studies or trials when they are available in your area.
  • Contact Alzheimer’s research centers or memory or neurology clinics in your community. They may be conducting trials.
  • Visit the Alzheimer’s and related Dementias Education and Referral (ADEAR) Center clinical trials finder.
  • Look for announcements in newspapers and other media.
  • Search

Why Would I Participate in a Clinical Trial?

There are many reasons why you might choose to join an Alzheimer’s or dementia clinical trial. You may want to:

  • Help others, including future family members, who may be at risk for Alzheimer’s disease or a related dementia
  • Receive regular monitoring by medical professionals
  • Learn about Alzheimer’s and your health
  • Test new treatments that might work better than those currently available
  • Get information about support groups and resources

What Else Should I Consider?

Consider both benefits and risks when deciding whether to volunteer for a clinical trial.

While there are benefits to participating in a clinical trial or study, there are some risks and other issues to consider as well.

Risk. Researchers make every effort to ensure participants’ safety. But, all clinical trials have some risk. Before joining a clinical trial, the research team will explain what you can expect, including possible side effects or other risks. That way, you can make an informed decision about joining the trial.

Expectations and motivations. Single clinical trials and studies generally do not have miraculous results, and participants may not benefit directly. With a complex disease like Alzheimer’s, it is unlikely that one drug will cure or prevent the disease.

Uncertainty. Some people are concerned that they are not permitted to know whether they are getting the experimental treatment or a placebo (inactive treatment), or may not know the results right away. Open communication with study staff can help you understand why the study is set up this way and what you can expect.

Time commitment and location. Clinical trials and studies last days to years. They usually require multiple visits to study sites, such as private research facilities, teaching hospitals, Alzheimer’s research centers, or doctors’ offices. Some studies pay participants a fee and/or reimburse travel expenses.

Study partner requirement. Many Alzheimer’s trials require a caregiver or family member who has regular contact with the person to accompany the participant to study appointments. This study partner can give insight into changes in the person over time.

What Happens When a Person Joins a Clinical Trial or Study?

Once you identify a trial or study you are interested in, contact the study site or coordinator. You can usually find this contact information in the description of the study, or you can contact the ADEAR Center. Study staff will ask a few questions on the phone to determine if you meet basic qualifications for the study. If so, they will invite you to come to the study site. If you do not meet the criteria for the study, don’t give up! You may qualify for a future study.

What Is Informed Consent?

It is important to learn as much as possible about a study or trial to help you decide if you would like to participate. Staff members at the research center can explain the study in detail, describe possible risks and benefits, and clarify your rights as a participant. You and your family should ask questions and gather information until you understand it fully.

After the research is explained and you decide to participate, you will be asked to sign an informed consent form, which states that you understand and agree to participate. This document is not a contract. You are free to withdraw from the study at any time if you change your mind or your health status changes.

Researchers must consider whether the person with Alzheimer’s disease or another dementia is able to understand and consent to participate in research. If the person cannot provide informed consent because of problems with memory and thinking, an authorized legal representative, or proxy (usually a family member), may give permission for the person to participate, particularly if the person’s durable power of attorney gives the proxy that authority. If possible, the person with Alzheimer’s should also agree to participate.

How Do Researchers Decide Who Will Participate?

Researchers carefully screen all volunteers to make sure they meet a study’s criteria.

After you consent, you will be screened by clinical staff to see if you meet the criteria to participate in the trial or if anything would exclude you. The screening may involve cognitive and physical tests.

Inclusion criteria for a trial might include age, stage of dementia, gender, genetic profile, family history, and whether or not you have a study partner who can accompany you to future visits. Exclusion criteria might include factors such as specific health conditions or medications that could interfere with the treatment being tested.

Many volunteers must be screened to find enough people for a study. Generally, you can participate in only one trial or study at a time. Different trials have different criteria, so being excluded from one trial does not necessarily mean exclusion from another.

Source link

Common Causes – CJ First Candle


There are many causes of stillbirth. More than one of these causes may be involved a the baby’s death. Other less common causes of stillbirth include trauma (such as car accidents), post-term pregnancy (longer than 42 weeks), Rh disease and lack of oxygen during a difficult delivery. Of the deaths where a cause has been found, following are some of the more common causes:

Birth Defects

Birth defects are involved in about 15 to 20 percent of all stillbirth deaths. Nearly half of these babies have a chromosomal abnormality, such as Down Syndrome. Others have birth defects resulting from genetic or environmental causes.

Placental Problems

Placental problems cause between 10 and 20 percent of stillbirths. Placental abruption is one of the most common placental problems. The placenta separates (partially or completely) from the uterine wall before delivery, resulting in heavy bleeding that can threaten the life of the mother and the baby. Women who smoke cigarettes or use drugs during pregnancy are at increased risk for placental abruption.

Poor Fetal Growth

Poor fetal growth accounts for about 20 percent of stillborn babies. This means that the fetus is growing too slowly. Women with pre-eclampsia (high blood pressure) are at an increased risk of having a growth-restricted baby. Smoking can also increase this risk. An ultrasound can help your doctor identify poor fetal growth and more closely monitor the pregnancy.

Cord Accidents

Accidents involving the umbilical cord may contribute to a stillbirth death in about 15 percent of the cases. This can include a knot in the cord or abnormal placement of the cord into the placenta. This can deprive the baby of oxygen.

Infectious Disease

Infections in the mother, baby or placenta seem to cause anywhere from 10 to 25 percent of stillbirths. Infections may not even cause symptoms for the mother, such as a genital and urinary tract infections or certain viruses such as parvovirus B19 (Fifth Disease). If these infections go undiagnosed, they can cause serious s complications such as fetal death or preterm birth.

Chronic Health Conditions

Chronic maternal health conditions are associated with about 10 percent of stillborn babies. These include high blood pressure, diabetes and kidney disease. These conditions can also contribute to poor fetal growth or placental abruption.  Fortunately, as a result of improvements in medical care, stillbirth deaths due to maternal health conditions have greatly decreased. Last revised: October 2009

Source link